HIIFS
URGN icon

Harel Insurance Investments & Financial Services’s UroGen Pharma URGN Stock Holding History

Harel Insurance Investments & Financial Services’s Portfolio URGN Stock Details URGN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q4 		– Sell
-82,772
Closed -$1.65M – 484
2025
Q3 		$1.65M Sell
82,772
-75,000
-48% -$1.35M 0.01% 163
2025
Q2 		$2.16M Sell
157,772
-216,210
-58% -$2.07M 0.02% 144
2025
Q1 		$4.14M Sell
373,982
-89,285
-19% -$952K 0.05% 123
2024
Q4 		$4.93M Hold
463,267
– – 0.08% 93
2024
Q3 		$5.88M Sell
463,267
-298
-0.1% -$4.42K 0.1% 68
2024
Q2 		$7.78M Sell
463,565
-209,922
-31% -$2.99M 0.15% 66
2024
Q1 		$10.1M Sell
673,487
-196,558
-23% -$3.21M 0.2% 54
2023
Q4 		$13.1M Sell
870,045
-149
-0% -$1.93K 0.23% 63
2023
Q3 		$12.2M Sell
870,194
-155,373
-15% -$2.49M 0.24% 66
2023
Q2 		$10.6M Sell
1,025,567
-301
-0% -$3.32K 0.26% 49
2023
Q1 		$9.48M Buy
1,025,868
+308
+0% +$2.83K 0.19% 72
2022
Q4 		$9.1M Sell
1,025,560
-23
-0% -$218 0.2% 65
2022
Q3 		$8.53M Sell
1,025,583
-28
-0% -$232 0.21% 77
2022
Q2 		$8.4M Sell
1,025,611
-22
-0% -$151 0.18% 84
2022
Q1 		$8.93M Sell
1,025,633
-42
-0% -$328 0.15% 86
2021
Q4 		$9.75M Buy
+1,025,675
New +$14.5M 0.18% 70
2019
Q3 		– Sell
-3,000
Closed -$108K – 573
2019
Q2 		$108K Buy
3,000
+1,000
+50% +$36.9K 0.01% 238
2019
Q1 		$74K Buy
2,000
+1,000
+100% +$41.9K ﹤0.01% 238
2018
Q4 		$43K Sell
1,000
-1,600
-62% -$71.9K ﹤0.01% 311
2018
Q3 		$123K Hold
2,600
– – 0.01% 253
2018
Q2 		$129K Buy
+2,600
New +$151K 0.01% 231

Other funds holding URGN

RI
RTW Investments New York $11.7B AUM 174.13% 1-Year Est. Return
PBA
Paradigm Biocapital Advisors New York $5.34B AUM 380.18% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
JFG
Jefferies Financial Group New York $15.2B AUM 55.75% 1-Year Est. Return
SCM
Silverarc Capital Management Boston, Massachusetts $962M AUM 524.64% 1-Year Est. Return
ACA
Acorn Capital Advisors New York $366M AUM 474.6% 1-Year Est. Return
SG Americas Securities
SG Americas Securities New York $179B AUM 65.34% 1-Year Est. Return
American Century Companies
American Century Companies Kansas City, Missouri $226B AUM 44.75% 1-Year Est. Return
MMH
Menora Mivtachim Holdings Ramat Gan, Israel $25.6B AUM 50.04% 1-Year Est. Return

Harel Insurance Investments & Financial Services's URGN Position: Q4 2025 in Review

Harel Insurance Investments & Financial Services sold out of UroGen Pharma (URGN) in Q4 2025, closing a stake of 82,772 shares — an estimated $1.65M sold.

Harel Insurance Investments & Financial Services first reported a position in URGN in Q2 2018 and held it in 21 quarters. The position peaked at $13.1M in Q4 2023. 167 funds tracked by Wall St. Rank hold URGN as of Q4 2025.

  • Harel Insurance Investments & Financial Services reported no remaining UroGen Pharma position as of Q4 2025 after selling out during the quarter.
  • Harel Insurance Investments & Financial Services sold 82,772 UroGen Pharma shares in Q4 2025, an estimated $1.65M.
  • Harel Insurance Investments & Financial Services first reported a position in UroGen Pharma in Q2 2018 and held it in 21 quarters.
  • Harel Insurance Investments & Financial Services's UroGen Pharma position peaked at $13.1M in Q4 2023.
  • 167 funds tracked by Wall St. Rank held UroGen Pharma as of Q4 2025.

Based on Harel Insurance Investments & Financial Services's 13F filing for Q4 2025, filed 3 Feb 2026.